Bharat Biotech Partners with Alopexx for Global Anti-Microbial Vaccine Development

Bharat Biotech announced a partnership with Alopexx Inc to co-develop and commercialize the broad-spectrum anti-microbial vaccine AV0328 in India and other low-income countries. The collaboration aims to reduce antimicrobial resistance through accessible vaccination, with both companies benefiting from potential sales and clinical advancements.

Bharat Biotech has entered into a partnership with Alopexx Inc to co-develop and commercialize the latter's broad-spectrum anti-microbial vaccine, AV0328, in India and other low-income nations.

The companies will work together to bring AV0328 to market, with Alopexx receiving an upfront payment, milestone payments, and future royalties from sales in licensed territories.

Bharat Biotech's Executive Chairman Krishna Ella emphasized the collaboration's alignment with their mission to provide high-quality vaccines. Alopexx CEO Daniel Vlock highlighted the partnership's importance for advancing affordable antimicrobial solutions globally. The phase I trial of AV0328 has already shown the vaccine to be well-tolerated with no serious adverse events.

(With inputs from agencies.)